• 34211 Citations
  • 69 h-Index
19972019
If you made any changes in Pure these will be visible here soon.

Research Output 1997 2019

Filter
Letter
2019
2 Citations (Scopus)

Adverse events 2.0—Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology

Heinzerling, L., Ascierto, P. A., Dummer, R., Gogas, H., Grob, J. J., Lebbe, C., Long, G. V., McArthur, G., Moslehi, J. J., Neilan, T. G., Ribas, A., Robert, C., Schadendorf, D., Wolchok, J. D. & Hauschild, A., May 1 2019, In : European Journal of Cancer. 112, p. 29-31 3 p.

Research output: Contribution to journalLetter

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., Svane, I. M., Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B., Ghori, R., Ibrahim, N., Moreno, B. H. & Ribas, A., Jun 1 2019, In : Nature Medicine. 25, 6, p. 941-946 6 p.

Research output: Contribution to journalLetter

Melanoma
Placebos
Blocking Antibodies
Mitogen-Activated Protein Kinase Kinases
Transaminases
2018
3 Citations (Scopus)

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

Italian Melanoma Intergroup (IMI), Jul 1 2018, In : European Journal of Cancer. 97, p. 59-61 3 p.

Research output: Contribution to journalLetter